Toca 511联合Toca FC对比标准治疗在复发性高级别胶质瘤术后生存的随机临床试验
TOCA 5是一项随机、开放标签2/3期试验,纳入403例首次或第二次复发的胶质母细胞瘤或间变性星形细胞瘤术后患者,1:1随机接受Toca 511/FC或标准治疗单药。
要点
- Toca 511/FC未改善复发性高级别胶质瘤术后总生存。
- 安全性方面两组不良事件发生率相似。
核心结论
- 在首次或第二次复发的胶质母细胞瘤或间变性星形细胞瘤术后患者中,Toca 511联合Toca FC对比标准治疗未改善总生存或其他疗效终点。
研究设计与样本
- 随机、开放标签2/3期试验(TOCA 5),在美国、加拿大、以色列和韩国58个中心开展,2015年11月30日至2019年12月20日。
- 403例患者1:1随机至Toca 511/FC组(n=201)或标准治疗对照组(n=202);所有随机患者纳入疗效分析,400例纳入安全性分析(标准治疗组3例未接受切除术)。
- 标准治疗对照组由研究者选择单药治疗:洛莫司汀、替莫唑胺或贝伐珠单抗。
主要发现
- 最终分析共271例死亡(Toca 511/FC组141例,标准治疗组130例),中位随访22.8个月。
- 次要终点未显示统计学显著差异,两组不良事件发生率相似。
关键数值与推荐
- 患者中位(SD)年龄56(11.46)岁,男性占62.5%(252/403)。
- 12个月OS及其他次要终点(持久缓解率、持久临床获益率、按IDH1变异状态分析的OS和DRR)未显示统计学显著差异。
临床怎么用
- 对于首次或第二次复发的胶质母细胞瘤或间变性星形细胞瘤术后患者,Toca 511/FC不应替代标准治疗。
- 临床决策仍应基于研究者选择的标准化疗或靶向治疗(洛莫司汀、替莫唑胺或贝伐珠单抗)。
- 该联合方案未显示生存获益,不推荐用于常规临床实践。
局限性
- 标准治疗对照组为研究者选择的单药治疗,非统一方案,可能影响组间比较。
- 开放标签设计可能引入偏倚。
- 最终分析时随访时间有限(中位22.8个月),长期生存数据不完整。
- 安全性分析中标准治疗组3例未接受切除术,与随机分组不完全一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: New treatments are needed to improve the prognosis of patients with recurrent high-grade glioma. OBJECTIVE: To compare overall survival for patients receiving tumor resection followed by vocimagene amiretrorepvec (Toca 511) with flucytosine (Toca FC) vs standard of care (SOC). DESIGN, SETTING, AND PARTICIPANTS: A randomized, open-label phase 2/3 trial (TOCA 5) in 58 centers in the US, Canada, Israel, and South Korea, comparing posttumor resection treatment with Toca 511 followed by Toca FC vs a defined single choice of approved (SOC) therapies was conducted from November 30, 2015, to December 20, 2019. Patients received tumor resection for first or second recurrence of glioblastoma or anaplastic astrocytoma. INTERVENTIONS: Patients were randomized 1:1 to receive Toca 511/FC (n = 201) or SOC control (n = 202). For the Toca 511/FC group, patients received Toca 511 injected into the resection cavity wall at the time of surgery, followed by cycles of oral Toca FC 6 weeks after surgery. For the SOC control group, patients received investigators' choice of single therapy: lomustine, temozolomide, or bevacizumab. MAIN OUTCOMES AND MEASURES: The primary outcome was overall survival (OS) in time from randomization date to death due to any cause. Secondary outcomes reported in this study included safety, durable response rate (DRR), duration of DRR, durable clinical benefit rate, OS and DRR by IDH1 variant status, and 12-month OS. RESULTS: All 403 randomized patients (median [SD] age: 56 [11.46] years; 62.5% [252] men) were included in the efficacy analysis, and 400 patients were included in the safety analysis (3 patients on the SOC group did not receive resection). Final analysis included 271 deaths (141 deaths in the Toca 511/FC group and 130 deaths in the SOC control group). The median follow-up was 22.8 months. The median OS was 11.10 months for the Toca 511/FC group and 12.22 months for the control group (hazard ratio, 1.06; 95% CI 0.83, 1.35; P = .62). The secondary end points did not demonstrate statistically significant differences. The rates of adverse events were similar in the Toca 511/FC group and the SOC control group. CONCLUSIONS AND RELEVANCE: Among patients who underwent tumor resection for first or second recurrence of glioblastoma or anaplastic astrocytoma, administration of Toca 511 and Toca FC, compared with SOC, did not improve overall survival or other efficacy end points. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02414165.
引用
- Cloughesy TF, Petrecca K, Walbert T, et al. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 33119048. doi:10.1001/jamaoncol.2020.3161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。